The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog.
Open Access
- 1 December 1976
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 58 (6) , 1407-1418
- https://doi.org/10.1172/jci108596
Abstract
The aim of the present experiments was to determine the role of insulin and glucagon in the regulation of basal glucose production in dogs fasted overnight. A deficiency of either or both pancreatic hormones was achieved by infusin somatostatin (1 mug/kg per min), a potent inhibitor of both insulin and glucagon secretion, alone or in combination with intraportal replacement infusions of either pancreatic hormone. Infusion of somatostatin alone caused the arterial levels of insulin and glucagon to drop rapidly by 72+/-6 and 81+/-8%, respectively. Intraportal infusion of insulin and glucagon at rates of 400 muU/kg per min and 1 ng/kg per min, respectively, resulted in the maintenance of the basal levels of each hormone. Glucose production was measured using tracer (primed constant infusion of [3-3H]glucose) and arteriovenous difference techniques. Isolated glucagon deficiency resulted in a 35+/-5% (P less than 0.05) rapid and sustained decrease in glucose production which was abolished upon restoration of the plasma glucagon level. Isolated insulin deficiency resulted in a 52+/-16% (P less than 0.01) increase in the rate of glucose production which was abolished when the insulin level was restored. Somatostatin had no effect on glucose production when the changes in the pancreatic hormone levels which it normally induces were prevented by simultaneous intraportal infusion of both insulin and glucagon. In conclusion, in the anesthetized dog fasted overnight; (a) basal glucagon is responsible for at least one-third of basal glucose production, (b) basal insulin prevents the increased glucose production which would result from the unrestrained action of glucagon, and (c) somatostatin has no acute effects on glucose turnover other than those it induces through perturbation of pancreatic hormone secretion. This study indicates that the opposing actions of the two pancreatic hormones are important in the regulation of basal glucose production in the postabsorptive state.Keywords
This publication has 54 references indexed in Scilit:
- Does somatostatin inhibition of insulin secretion involve two mechanisms of action?Proceedings of the National Academy of Sciences, 1976
- The role of glucagon in the pathogenesis of the endogenous hyperglycemia of diabetes mellitusMetabolism, 1975
- Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogsMetabolism, 1975
- Estimation of pancreatic IRI output rate and its relation to glucose tolerance in normal anaesthetized dogsDiabetologia, 1975
- Gluconeogenesis from Alanine in Normal Postabsorptive Man: Intrahepatic Stimulatory Effect of GlucagonDiabetes, 1975
- Comparison of Cyclic and Linear Forms of Somatostatin in the Inhibition of Growth Hormone, Insulin and Glucagon Secretion1Journal of Clinical Endocrinology & Metabolism, 1975
- Persistent Pancreatic Glucagon but not Insulin Response to Arginine in Pancreatectomized DogsEndocrinology, 1975
- High Molecular Weight Glucagon-like Immunoreactivity in Plasma1Journal of Clinical Endocrinology & Metabolism, 1975
- Studies on the inhibition of insulin release, glycogenolysis and gluconeogenesis by somatostatin in the rat islets of Langerhans and isolated hepatocytesBiochemical and Biophysical Research Communications, 1975
- Evidence for a physiologic role of pancreatic glucagon in human glucose homeostasis: Studies with somatostatinMetabolism, 1975